Thalidomide for inflammatory bowel disease

Bramuzzo, Matteo; Ventura, Alessandro; Martelossi, Stefano; Lazzerini, Marzia

doi:10.1097/md.0000000000004239

Cited by 38 publications

(27 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to medical reimbursement policy in China, a large number of refractory CD patients who cannot afford biologics such as infliximab, and thalidomide is a good option for them in such circumstance. [46][47][48] More patients with different types of therapies will be included in future studies based on a great change in reimbursement policy recently, such as infliximab using, in China. Finally, a comparison of AMH levels before and after medical treatment is needed in a longitudinal study with more patients using biologics.…”

Section: Discussionmentioning

confidence: 99%

Risk Factors Associated with Impaired Ovarian Reserve in Young Women of Reproductive Age with Crohn’s Disease

Zhao

Chen

et al. 2020

Intest Res

View full text Add to dashboard Cite

Background/Aims: Crohn’s disease (CD) primarily affects young female adults of reproductive age. Few studies have been conducted on this population’s ovarian reserve status. The aim of study was to investigate potential risk factors associated with low ovarian reserve, as reflected by serum anti-Müllerian hormone (AMH) in women of reproductive age with CD.Methods: This was a case-control study. Cases included 87 patients with established CD, and healthy controls were matched by age, height and weight in a 1:1 ratio. Serum AMH levels were measured by enzyme-linked immunosorbent assay.Results: The average serum AMH level was significantly lower in CD patients than in control group (2.47±2.08 ng/mL vs. 3.87±1.96 ng/mL, respectively, P<0.001). Serum AMH levels were comparable between CD patients and control group under 25 years of age (4.41±1.52 ng/mL vs. 3.49±2.10 ng/mL, P=0.06), however, serum AMH levels were significantly lower in CD patients over 25 years of age compared to control group (P<0.05). Multivariable analysis showed that an age greater than 25 (odds ratio [OR], 10.03; 95% confidence interval [CI], 1.90–52.93, P=0.007), active disease state (OR, 27.99; 95% CI, 6.13–127.95, P<0.001) and thalidomide use (OR, 15.66; 95% CI, 2.22–110.65, P=0.006) were independent risk factors associated with low ovarian reserve (serum AMH levels <2 ng/mL) in CD patients. Conclusions: Ovarian reserve is impaired in young women of reproductive age with CD. Age over 25 and an active disease state were both independently associated with low ovarian reserve. Thalidomide use could result in impaired ovarian reserve.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk Factors Associated with Impaired Ovarian Reserve in Young Women of Reproductive Age with Crohn’s Disease

Zhao

Chen

et al. 2020

Intest Res

View full text Add to dashboard Cite

show abstract

“…Given its significant efficacy, thalidomide has been approved by FDA for the treatment of Erythema Nodosum Leprosum and multiple myeloma. Presently, due to its immune‐modulatory effect thalidomide is commonly used inflammatory bowel disease . Thalidomide is given orally with a dose ranging from 100 to 1000 mg per day; it is mostly spontaneously hydrolyzed and therefore dose adjustment is not required in hepatic or renal impairment.…”

Section: Oncological Use Dose and Neurotoxicitymentioning

confidence: 99%

Vinca alkaloids, thalidomide and eribulin‐induced peripheral neurotoxicity: From pathogenesis to treatment

Islam

Lustberg

Staff

et al. 2019

J Peripheral Nervous Sys

View full text Add to dashboard Cite

Vinca alkaloids, thalidomide, and eribulin are widely used to treat patients with childhood acute lymphoblastic leukemia (ALL), adults affected by multiple myeloma and locally invasive or metastatic breast cancer, respectively. However, soon after their introduction into clinical practice, chemotherapy-induced peripheral neurotoxicity (CIPN) emerged as their main non-hematological and among dose-limiting adverse events. It is generally perceived that vinca alkaloids and the antiangiogenic agent thalidomide are more neurotoxic, compared to eribulin. The exposure to these chemotherapeutic agents is associated with an axonal, length-dependent, sensory polyneuropathy of mild to moderate severity, whereas it is considered that the peripheral nerve damage, unless severe, usually resolves soon after treatment discontinuation. Advanced age, high initial and prolonged dosing, coadministration of other neurotoxic chemotherapeutic agents and pre-existing neuropathy are the common risk factors. Pharmacogenetic biomarkers might be used to define patients at increased susceptibility of CIPN. Currently, there is no established therapy for CIPN prevention or treatment; symptomatic treatment for neuropathic pain and dose reduction or withdrawal in severe cases is considered, at the cost of reduced cancer therapeutic efficacy. This review critically examines the pathogenesis, epidemiology, risk factors (both clinical and pharmacogenetic), clinical phenotype and management of CIPN as a result of exposure to vinca alkaloids, thalidomide and its analogue lenalidomide as also eribulin. K E Y W O R D S assessment, eribulin, peripheral neurotoxicity, thalidomide, vinca alkaloids

show abstract

“…Thalidomide is an immunosuppressant drug used rarely in the treatment of refractory CD and UC[ 47 ]. Its mechanism of action includes several pathways such as inhibition of TNF, IFN-γ and IL-12, stimulation of IL-4 and IL-5 production and, more broadly, a shift in the pattern of lymphocyte cytokine from a Th1 (IFN-γ, IL-12) to Th2 (IL-4, IL-5) type[ 5 ].…”

Section: Thalidomidementioning

confidence: 99%

Treating children with inflammatory bowel disease: Current and new perspectives

Guariso

Gasparetto

2017

WJG

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gut characterised by alternating periods of remission and relapse. Whilst the mechanism underlying this disease is yet to be fully understood, old and newer generation treatments can only target selected pathways of this complex inflammatory process. This narrative review aims to provide an update on the most recent advances in treatment of paediatric IBD. A MEDLINE search was conducted using “paediatric inflammatory bowel disease”, “paediatric Crohn’s disease”, “paediatric ulcerative colitis”, “treatment”, “therapy”, “immunosuppressant”, “biologic”, “monitoring” and “biomarkers” as key words. Clinical trials, systematic reviews, and meta-analyses published between 2014 and 2016 were selected. Studies referring to earlier periods were also considered in case the data was relevant to our scope. Major advances have been achieved in monitoring the individual metabolism, toxicity and response to relevant medications in IBD including thiopurines and biologics. New biologics acting on novel mechanisms such as selective interference with lymphocyte trafficking are emerging treatment options. Current research is investing in the development of reliable prognostic biomarkers, aiming to move towards personalised treatments targeted to individual patients.

show abstract

Thalidomide for inflammatory bowel disease

Abstract: Supplemental Digital Content is available in the text

Cited by 38 publications

References 44 publications

Risk Factors Associated with Impaired Ovarian Reserve in Young Women of Reproductive Age with Crohn’s Disease

Risk Factors Associated with Impaired Ovarian Reserve in Young Women of Reproductive Age with Crohn’s Disease

Vinca alkaloids, thalidomide and eribulin‐induced peripheral neurotoxicity: From pathogenesis to treatment

Treating children with inflammatory bowel disease: Current and new perspectives

Contact Info

Product

Resources

About